Advertisement

Topics

Biotechnology Clinical Trials

12:38 EST 23rd January 2019 | BioPortfolio

Impact of AferBio® on Quality of Life and Chemotherapy Toxicity in Lung Cancer Patients

The AFERBIO study will evaluates safety and potential benefit of AferBio® in patients with non-small cell lung cancer undergoing at least a second-line palliative monochemotherapy. AferBio® is a fermented supplement in powder form obtained through biotechnological processes developed in Brazil. In this double-blind placebo-controlled randomized clinical trial, participant...

Salivary Antioxidant Capacity Before and After Complete Dental Rehabilitation

Salivary samples were obtained from 20 children in their fifth year of life diagnosed S-ECC and 20 age and sex matched controls. Complete dental rehabilitation under general anesthesia was performed for the 20 children with S-ECC, and follow up salivary samples were obtained one week and three months post operatively. The TAC was measured using a commercially available Oxyg...

Neuromed- Integrated Health Life Platform and Biobank

This project aims to create a digital platform for personal, clinical, diagnostic and environmental data collection, management and analysis of patients with cardiovascular and neurological disease or cancer admitted to the Neuromed Group clinics, associated with a biobanks of biological fluids and human tissues and a biotechnological platform for "omics" analysis, to encou...

RESULT: Reliable, Emergent Solution Using Liprotamase Treatment

Liprotamase powder is a non-porcine, soluble and stable mixture of biotechnology-derived lipase, protease, and amylase digestive enzymes. The purpose of the present study is to to evaluate the non-inferiority of liprotamase compared with porcine-derived, enterically-coated pancreatic enzyme replacement therapy (PERT). The primary efficacy endpoint of the study will be compa...

A Phase III Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants

In order to evaluate immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine produced by Beijing Minhai Biotechnology Co., Ltd., a randomized, double-blind, parallel-controlled phase III clinical trial is planned to conduct in healthy infants aged 3-6 months in China.

A Pilot Scheme - Specimen Collection of Health Management Center

Biomedical and biotechnology industry is internationally regarded as the most brilliant star performer of the future. The development of biomedical depends on a high quality academic research environment, while innovation and uniqueness should be emphasized for the development of biotechnology industry. The successful development of biotechnology industry will be impossible...

Dose Escalation Study to Evaluate Oral Rotavirus Vaccine 116E Live Attenuated in Healthy Infants 8 to 20 Weeks Old

This study will be a Phase I, randomized, double blind, safety and immunogenicity trial of the Vero cell based 116E neonatal rotavirus vaccine candidate strain in healthy non-malnourished infants aged 8-20 weeks at three different dosage levels i.e.10^4.0, 10^5.0 and 10^6.0 FFU and for three administrations of each of these dosages given to infants at 4-week intervals. 180 ...

Advertisement
Quick Search
Advertisement
Advertisement

 

review and buy Biotechnology market research data and corporate reports here